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ABSTRACT (words = 227)  
Trabecular bone score (TBS) is a recently-developed analytical tool that performs novel grey-
level texture measurements on lumbar spine dual X-ray absorptiometry (DXA) images, and 
thereby captures information relating to trabecular microarchitecture. In order for TBS to 
usefully add to bone mineral density (BMD) and clinical risk factors in osteoporosis risk 
stratification, it must be independently associated with fracture risk, readily obtainable, and 
ideally, present a risk which is amenable to osteoporosis treatment. This paper summarizes a 
review of the scientific literature performed by a Working Group of the European Society for 
Clinical and Economic Aspects of Osteoporosis and Osteoarthritis. Low TBS is consistently 
associated with an increase in both prevalent and incident fractures that is partly independent 
of both clinical risk factors and areal BMD (aBMD) at the lumbar spine and proximal femur.  
More recently, TBS has been shown to have predictive value for fracture independent of 
fracture probabilities using the FRAX® algorithm. Although TBS changes with osteoporosis 
treatment, the magnitude is less than that of aBMD of the spine, and it is not clear how change 
in TBS relates to fracture risk reduction. TBS may also have a role in the assessment of fracture 
risk in some causes of secondary osteoporosis (e.g. diabetes, hyperparathyroidism and 
glucocorticoid-induced osteoporosis).  In conclusion, there is a role for TBS in fracture risk 
assessment in combination with both aBMD and FRAX.  
 
KEY WORDS: osteoporosis; epidemiology; trabecular bone score (TBS); fragility fracture; bone 
mineral density; FRAX. 
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Introduction 
Osteoporosis, fragility fractures and risk assessment 
Measurements of bone mineral density (BMD) are a central component of any provision that 
arises from the definition of osteoporosis, agreed internationally as: a progressive systemic 
skeletal disease characterized by low bone mass and microarchitectural deterioration of bone 
tissue, with a consequent increase in bone fragility and susceptibility to fracture [1].  This 
definition captures the notion that low areal BMD (aBMD) is an important component of 
fracture risk, but that other bone abnormalities contribute to skeletal fragility. The conceptual 
description of osteoporosis thus centres both on the assessment of bone mass and quality, 
specifically bone microstructure. Until recently, there were no satisfactory clinical means to 
assess bone microstructure non-invasively, so that the operational diagnosis of osteoporosis is 
based on the measurement of aBMD.  Osteoporosis is so-defined as a femoral neck aBMD 2·5 
SD or more below the young adult female mean (T-score <–2·5) [2, 3].  The same T-score 
derived at other sites is widely used in clinical practice (e.g. lumbar spine, total hip, distal 
radius). 
A consequence of this operational definition, which identifies the small proportion of the 
population at highest risk, is that the greater number of individuals above this threshold, 
although individually at lower risk, contribute the greater number of fractures to the total 
burden. Indeed, the majority of fragility fractures occur in patients who have an aBMD T-score 
>-2.5. In other words, the detection rate for these fractures (sensitivity) is low [4], which is why 
widespread population-based screening is not generally recommended in women at 
menopause [2, 5]. Thus, factors other than bone mass influence bone strength and fracture 
risk, including microarchitectural deterioration of bone tissue, as given in the conceptual 
definition of osteoporosis.  Additional skeletal and extra-skeletal factors, such as bone 
geometry, micro-damage, mineralization, bone turnover, age, and a large range of clinical risk 
factors, including family history, prior fracture and fall risk, contribute to the overall assessment 
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of fracture risk [6-9].  Several of these additional factors are captured by FRAX®.  FRAX 
estimates the 10-year probability of hip and major osteoporotic fracture based on the 
individual’s risk factor profile [4].  Apart from BMD, FRAX does not capture other skeletal 
determinants of bone strength that improve upon or are at least partly independent of aBMD 
[10].  Several such determinants are the subject of clinical research [11-18] using novel imaging 
techniques, such as Quantitative Computed Tomography (QCT) and high resolution (peripheral) 
QCT [19, 20], and minimally invasive approaches for probing bone material properties, notably 
microindentation techniques [21].  Although there is evidence of their predictive ability for 
fracture [22, 23] , none of these modalities appears to reliably outperform aBMD in the 
prediction of the various types of osteoporotic fractures, and their general lack of availability 
and validation in the clinical setting means that an adjunctive role alongside DXA-measured 
aBMD is unlikely to be feasible in most settings in the near future. In contrast, trabecular bone 
score (TBS) is a novel imaging technique, based on standard DXA images, and appears to 
constitute an index of bone texture that provides skeletal information additional to the 
standard aBMD results [24]. 
Trabecular bone score: definition 
TBS has emerged as a novel grey-level texture measurement that uses experimental variograms 
of 2D projection images, quantifying variation in grey-level texture from one pixel to the 
adjacent pixels. TBS is not a direct measurement of bone microarchitecture but it is related to 
3D bone characteristics such as the trabecular number, the trabecular separation and the 
connectivity density [25, 26]. An elevated TBS appears to represent strong, fracture-resistant 
microarchitecture, while a low TBS reflects weak, fracture-prone microarchitecture. As such, 
there is evidence that TBS can differentiate between two 3-dimensional (3D) microarchitectures 
that exhibit the same bone density, but different trabecular characteristics. TBS is generally 
obtained by re-analysis of AP lumbar spine DXA images, which allows direct comparison with 
aBMD and application to existing datasets. This latter opportunity has led to a rapid rise in 
published research assessing its potential role in the assessment and management of 
osteoporosis. 
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Lumbar TBS, like aBMD, is an age dependent variable. Little change in TBS is observed between 
the ages of 30 and 45 years. Thereafter, a progressive decrease is observed with advancing age 
[27], which is more marked in women than in men. The percentage decrease with age is similar 
to that for lumbar spine aBMD, as is the short term reproducibility [25]. 
This paper reports the findings of a European Society for Clinical and Economic Aspects 
of Osteoporosis and Osteoarthritis (ESCEO) Working Group, which first convened in September 
2014 with the aim of comprehensively assessing the evidence supporting the use of TBS in 
clinical practice. More specifically, this report reviews the potential value of TBS as an 
independent adjunct to risk assessment using DXA aBMD and/or FRAX in settings such as post-
menopausal and secondary osteoporosis, and its potential use in assessment of response to 
treatment.  
Search Strategy 
A Medline search for publications with the terms trabecular bone score or TBS was undertaken 
in September 2014.  Published articles in English and French were extracted.  Papers in abstract 
form were not included except where the authors supplied a full copy of the submitted 
manuscript.  A total of 479 papers were identified of which 67 manuscripts were considered 
relevant and the full publication reviewed.  The search was subsequently updated in February 
2015 and a total of 73 papers were reviewed. 
Does TBS predict osteoporosis-related fracture risk?  
To date, eighteen studies assessing fracture risk in post-menopausal women have been 
published. Of these, eleven were cross-sectional [28-38] and seven prospective, including a  
meta-analysis [25, 39-44].  
Cross-sectional studies 
The eleven cross-sectional studies are summarized in Table 1. The studies all were published 
from 2009 onward to January 2015. Sample sizes ranged from 135 to 3069, with the majority 
between 150 and 300 subjects. Six of the studies exclusively involved post-menopausal women, 
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while one included only men over 40 years [31], and another both men and women over 50 
years who had suffered at least one prior fracture [33]. There was variation in which fractures 
were assessed and how the fractures were ascertained. For example, five studies used self-
report for all fractures, though vertebral fracture assessments (VFA) were used to identify 
vertebral fractures in three studies. In every study, however, and for every fracture type, there 
were significantly increased odds of prior fracture among those with low TBS even when 
adjusted for age, lumbar aBMD, body mass index, and clinical risk factors.  Moreover, in one 
study which reported area (AUC) under receiver operating curves (ROC) as a combined measure 
of sensitivity and specificity, the AUC for TBS was greater than for aBMD of the spine (0.67 vs. 
0.54, p = 0.035) but not for hip aBMD for subjects in the non-osteoporotic aBMD range [33]. 
However, in a further study which reported AUC values, these were similar for total hip BMD 
and total hip BMD with TBS (0.80 versus 0.81 respectively) [36]. 
Prospective studies 
Cross-sectional studies may not accurately quantify the utility of a measure in the longitudinal 
prediction of incident fractures. However, data from prospective studies have supported the 
findings from the cross-sectional investigations. Of the six prospective single studies, one was 
conducted in France [28], one in the UK, France and Germany [40], three in Canada [25, 43, 54], 
and one in Japan [41] (Table 2).  These cohorts tended to be larger than those in the cross-
sectional studies, with the smallest with 560 subjects and the largest over 33,000 post-
menopausal women; follow-up ranged from under 5 to over 8 years.  
By far the largest published study assessing TBS to date was conducted in the Canadian province 
of Manitoba [46, 47], comprising 29,407 postmenopausal women (all over 50 years, mean 65.4 
years) living in and around the capital city of Winnipeg [25]. At five years of follow-up, there 
were 1668 incident major osteoporotic fractures, including 439 vertebral fractures and 293 hip 
fractures. Lumbar spine aBMD and TBS predicted fractures equally well, and the combination of 
both performed better than either individually.  Interestingly, although aBMD-lumbar spine and 
aBMD-total hip were closely correlated (r = 0.72), aBMD-lumbar spine and TBS-lumbar spine 
were only weakly correlated (r = 0.32), with only 10% of the variance in one explained by 
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variance in the other. Similarly weak to moderate correlations between aBMD and TBS have 
been reported by several others [48-53], and may relate to measurement of different bone 
properties, or measurement variability. When various models adjusted for age  and clinical risk 
factors were tested for overall accuracy using receiver operating curves (ROC) and AUC 
estimates, the model combining aBMD-total hip and TBS-spine performed best, with AUC values 
for clinical vertebral and hip fractures of 0.73 (95%CI: 0.71, 0.75) and 0.82 (95%CI: 0.79, 0.84), 
respectively.  For femoral neck, total hip and lumbar aBMD, the AUC improved significantly 
(p<0.001) with the inclusion of TBS.  Fracture rate increased from highest to lowest third of TBS 
for subjects across the range of aBMD. 
A  smaller longitudinal study, conducted in France, was the OFELY (Osteoporose dans les 
Femmes de Lyon) study involving 560 post-menopausal women of mean age 65.3 years 
recruited in 2000 and 2001 and followed for a mean 7.8 years [39].  In this cohort there were 
112 incident fragility fractures that occurred in 92 women. Adjusted for age and prior fracture, 
TBS, lumbar spine and total hip aBMD were predictive of fracture occurrence. As with the 
Manitoba study, the AUC for a combined model of lumbar aBMD and TBS was better than that 
for either test used alone. TBS appeared to have the discriminative ability only in those women 
with normal or osteopenic aBMD but not for women in the osteoporotic aBMD range. For 
example, the incidence of fracture in osteopenic women with a TBS value in the lowest quartile 
was 25% compared to 13% in osteopenic women with TBS values in the remaining quartiles.  
The Japanese Population-Based Osteoporosis Cohort Study (JPOS) prospectively followed 665 
Japanese women over the age of 50 years (mean age 64.1 years) for evidence of new 
morphometric vertebral fractures (VF), over approximately ten years [41]. During follow-up, 92 
new vertebral fractures were documented by vertebral fracture assessment (VFA). In contrast to 
the OFELY study, there was an increased rate of VF from highest to lowest third of TBS score 
irrespective of BMD; i.e., also in those women in the osteoporotic aBMD range; the 
combination of aBMD and TBS increased overall performance of VF risk estimation over either 
used alone. 
In the Osteoporosis and Ultrasound Study (OPUS), 1007 post-menopausal women (mean age 
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65.9 years) were recruited from three European centres, one each in France, Germany and the 
UK, and followed for an average of 6.0 years [40]. Over those six years, there were 82 incident 
clinical fractures and 46 incident vertebral fractures identified by radiography. TBS and aBMD at 
lumbar spine, femoral neck or total hip were similarly predictive of fragility fractures, but the 
combination of TBS and aBMD performed better than either measure alone, both in 
osteoporotic and non-osteoporotic women. 
Only one longitudinal study on TBS has data for men (Table 2), with 3620 men over age 50 years 
(mean age 67.6 years) in the Manitoba cohort, followed for an average of 4.5 years and 
sustaining 183 major osteoporotic fractures [54]. TBS was predictive of hip, vertebral or major 
fractures. However, predictive power remained significant only for hip fracture when adjusted 
for FRAX score, osteoporosis treatment, and aBMD. There was some evidence of an interaction 
between aBMD and TBS such that the relationship between TBS and incident fracture appeared 
stronger in those with an aBMD T-score < -2.5. 
 A recent meta-analysis of 14 prospective population-based cohorts comprising 17,809 men and 
women (59% women) examined fracture risk expressed as a gradient of risk (GR, the increase in 
fracture risk/SD difference in TBS).  The GR of TBS for hip fracture or other major osteoporotic 
fracture (clinical spine, distal forearm or proximal humerus fracture) ranged from 1.31 to 1.54 
depending on age and fracture outcome with no difference between men and women [42]. 
These data support the utility of low lumbar TBS as a determinant of fracture risk, at least partly 
independent of aBMD.  The consistency of the predictive value for fracture in international 
cohorts argues for its clinical use with aBMD. 
 
Is TBS a potential adjunct to FRAX® probability? 
FRAX is widely used as a fracture risk assessment tool and the question arises whether TBS 
might serve as an adjunct to FRAX risk factors in the stratification of fracture risk. For TBS to be 
considered clinically useful as a FRAX modifier, it should be at least partly independent of 
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lumbar spine aBMD, femoral neck aBMD and FRAX clinical risk factors (CRFs). An assessment of 
the relationship between CRFs, aBMD and TBS was undertaken in the Manitoba cohort, in which 
33,352 women aged 40–100 years (mean 63 years) with baseline DXA measurements of lumbar 
spine TBS and femoral neck aBMD were studied [43]. Over a mean of 4.7 years follow-up, 1,754 
women died and 1,872 sustained one or more major osteoporotic fracture. Lower TBS predicted 
increased risk of incident fracture (HR/SD decrease: 1.36; 95%CI: 1.30, 1.42, p<0.001) and a 32% 
increase in death rate (HR/SD decrease: 1.32; 95%CI: 1.26, 1.39, p < 0.001). Lumbar spine TBS 
remained a significant predictor of major osteoporotic fracture (HR/SD decrease: 1.18; 95 %CI: 
1.12, 1.23) after adjustment for significant clinical risk factors and femoral neck aBMD. Low TBS 
(10th percentile) increased fracture risk 1.5 to 1.6-fold relative to high TBS (90th percentile), 
after accounting for competing mortality, across a wide range of ages and femoral neck T-
scores. 
Similar results were found in 3620 men from the Manitoba cohort at the age of  50 years or 
more (mean 67.6 years) [54]. Over a mean follow-up of 4.5 years, 183 men sustained major 
osteoporotic fractures and 91 clinical vertebral fractures. Lower lumbar spine TBS was observed 
in fracture versus non-fracture men for all fracture categories, and the AUC for incident fracture 
discrimination with TBS was significantly better than by chance (major osteoporotic fracture 
AUC = 0.59, p<0.001; hip fracture AUC = 0.67, p<0.001; clinical vertebral fracture AUC = 0.57, p = 
0.032). After adjustment for FRAX without aBMD and osteoporosis treatment, TBS predicted 
major osteoporotic fracture and hip fracture (but not clinical vertebral fracture), and remained a 
predictor of hip fracture (but not major osteoporotic fracture) after further adjustment for hip 
or spine aBMD. 
More recently, Manitoba data have been used to derive an adjustment factor to alter FRAX 
probabilities when accounting for TBS [55]. Data from 33,352 women between the ages of 40 
and 100 years in Manitoba were used, including baseline DXA measures of femoral neck aBMD 
and lumbar spine TBS. Hazard functions for risk of osteoporotic fracture without hip fracture, 
hip fracture, and death (since risk of death competes with risk of fracture) were used to 
compute the adjustment factor. Femoral neck aBMD, clinical risk factors and TBS all contributed 
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independent predictive value to the models, and TBS modified the 10-year probability of 
fracture outcomes generated from clinical risk factors and aBMD in FRAX-like models. Thus, for 
example, in an 80-year old women, with a femoral neck T score of -2, and BMI 27kg/m2, the 10-
year probability of major osteoporotic fracture was 16.5%. If her TBS were found to be low (10th 
percentile), this would increase her fracture probability to 18.0%; conversely if TBS were found 
to be high (90th percentile), her fracture probability would be reduced to 13.6%. 
The validity of the adjustment to FRAX has been explored in a meta-analysis of 14 cohorts 
(excluding Manitoba), together incorporating 17,809 men and women (59% women) ranging in 
age from 40 to 90 years (mean age 72 years) [42]. FRAX and TBS both had predictive ability for 
both major osteoporotic fractures and hip fracture, partly independently of each other. The 
predictive ability of FRAX was expressed as the gradient of risk (GR; hazard ratio per 1SD change 
in risk variable in direction of increased risk). Overall, the GR of TBS for major osteoporotic 
fracture was 1.44 (95%CI: 1.35-1.53) when adjusted for age and time since baseline and was 
similar in men and women (p>0.10).  When additionally adjusted for FRAX 10-year probability of 
major osteoporotic fracture, TBS remained a significant, independent predictor for fracture (GR 
1.32, 95%CI: 1.24-1.41).  The adjustment of FRAX probability for TBS resulted in a small increase 
in the GR (1.76, 95%CI: 1.65-1.87 vs. 1.70, 95%CI: 1.60-1.81) suggesting that TBS would have 
clinical utility, for example, in the reclassification of those close to intervention thresholds.  
 
Is TBS responsive to treatment? 
Several relatively small studies have examined treatment-induced changes in TBS [49,50, 53, 56-
59] (Table 3).  Of these, four were studies of osteoporosis treatment in postmenopausal women, 
one in both men and women with osteoporosis, and two in the management of breast cancer.  
One of these compared a specific oestrogen-receptor modifier (tamoxifen) and an aromatase 
inhibitor (exemestane) in breast cancer patients.  
In Manitoba, 534 post-menopausal women treated with a bisphosphonate (86%), raloxifene 
(10%) or calcitonin (4%), and having more than 75% compliance, were compared with 1,150 
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untreated women [50]. The mean duration of follow-up was 3.7 years. Women in the treated 
group were older (mean age 66.1 vs. 62.2 years), had lower scores for aBMD and lumbar TBS, 
and had a higher prevalence of prior major osteoporotic fracture (15.4 vs. 10.4%) at baseline, 
consistent with indications for treatment. Over the course of follow-up, spine aBMD and TBS 
increased in treated women by 1.9% and 0.2%, respectively, whereas in untreated women 
aBMD and TBS decreased by 0.4% and 0.3% (all statistically significant changes versus baseline). 
Changes in aBMD and TBS from baseline were only weakly correlated (r = 0.20), consistent with 
the notion that the two indices represent partly independent measures of bone structure. 
In the Swiss Horizon trial, 54 post-menopausal women treated with zoledronic acid were 
compared with 53 on placebo over 36 months of follow-up [52, 53]. The only clinically-
meaningful difference in baseline characteristics was a lower lumbar spine T-score in treated 
women (-2.9 vs. -2.1). Over three years, lumbar spine aBMD and TBS rose significantly, by 9.6% 
and 1.4%, respectively, in those on active treatment. The spine aBMD T-score also rose by 1.4% 
in those on placebo, perhaps due to degenerative disease, whilst TBS declined by 0.5%. The first 
statistically-significant change from baseline for aBMD was recorded at 6 months, whereas for 
TBS was at 24 months. Changes in the aBMD and TBS were only weakly correlated (r = 0.20) [52, 
53] . 
In a two-year open-label study [59] comparing teriparatide (n = 65) and ibandronate (n = 122), 
in which the only clinically-significant inter-group difference in baseline characteristics was a 
higher prevalence of past vertebral fractures in those on teriparatide (90.5 vs. 44.3%), patients 
on teriparatide had 7.6 and 4.3% increases in lumbar aBMD and TBS (both p < 0.001 vs. 
baseline), whilst only aBMD increased significantly in those on ibandronate (2.9% vs. 0.03%; p < 
0.001 and 0.086, respectively). In this study, there was no significant correlation between 
changes in aBMD and TBS (r2 = 0.01). In this report, responsivity was also assessed as the 
proportion of patients achieving the least significant change in TBS and aBMD.  For both 
treatment modalities lumbar spine BMD was more sensitive than TBS. 
In an analysis of a small subset of treated female breast cancer patients in the Tamoxifen 
Exemestane Adjuvant Multicentre (TEAM) trial (n = 19 on exemestane, 17 on tamoxifen) [49], 
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spine aBMD and TBS increased by 1.9 and 3.3% in those on tamoxifen versus a 5.3 and 2.3% 
decrease in patients given exemestane. The disparate responses to the two drugs are consistent 
with prior research demonstrating decreased fracture risk in postmenopausal breast cancer 
patients treated with tamoxifen and the increased risk observed in those on exemestane [60-
62]. Changes in TBS and aBMD were again only weakly correlated (r = 0.25) [49]. 
A double-blind, randomized, placebo-controlled trial evaluated the effect of 8 cycles of adjuvant 
treatment with zoledronic acid over a 24-month period (4 mg i.v. once every 3 months) 
compared to placebo on aBMD and TBS in premenopausal women with estrogen receptor 
and/or progesterone receptor positive breast cancer [57].  Treatment induced increases in both 
aBMD and TBS which were somewhat greater in percentage terms in the case of aBMD.  
A cohort of 390 patients was analysed to evaluate the effect of different treatments          
(testosterone, risedronate, alendronate, denosumab, teriparatide) on aBMD and TBS [56].  After 
24 months, a significant increase in TBS was observed only in the alendronate (+1.4%), 
denosumab (+2.8%) and teriparatide (+3.6%) groups, whereas aBMD increases in all treated 
groups. TBS was preserved on calcium and vitamin D, and decreased in the group without any 
treatment consistent with an epidemiological study showing that lower intakes of milk were 
associated with lower values for aBMD and TBS [63]. 
Longitudinal assessment of change represents a number of challenges both for bone 
densitometry and the evaluation of TBS. The precision of the measurement is critical, both 
within and between instruments [64]. However, sensitivity to measure changes is also affected 
by responsiveness, the ratio of responsiveness to precision being an indicator of sensitivity to 
measure (treatment-induced) changes [65]. At present, treatment induced changes in TBS have 
not been consistently assessed in this way. Nor has any possible contribution of TBS to fracture 
efficacy been explored, given that  the change in aBMD with treatment does not appear to fully 
explain the magnitude of fracture risk reduction [66;67].  
Taken together, these intervention studies suggest that TBS tends to increase with treatments 
which increase aBMD, but that the magnitude of change of TBS is less marked than that of 
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aBMD. It is currently unclear whether TBS might usefully contribute to the monitoring of 
treatment effects; and, given that DXA appears more responsive to change, this seems an 
unlikely outcome. However, these studies do indicate that TBS is potentially amenable to 
change as a result of pharmacological therapy. Whether this change is predictive of alterations 
in risk of future fracture, however, is currently not known.  
 
Does TBS have a role in secondary osteoporosis? 
Although in many cases, osteoporosis is idiopathic, there are a number of specific causes of 
bone fragility that result in “secondary osteoporosis”. Evidence is emerging that TBS might 
provide useful information with regards to bone health in several clinical contexts [68].  
Clinical and subclinical hypercortisolism 
Glucocorticoid induced osteoporosis (GIO) is common. Patients on long-term glucocorticoids 
fracture at a higher BMD than postmenopausal women, potentially implying a deleterious effect 
on bone structure. These effects may be more pronounced at lumbar spine; thus TBS may be 
well positioned to detect GIO-associated changes in bone structure.  
In a cross-sectional study 65, women with systemic sclerosis were matched with 138 women 
with rheumatoid arthritis and 227 controls [69].  Multivariate analysis showed that a low TBS 
was independently associated with daily glucocorticoid dose.  In a comparison of 34 patients 
with adrenal tumour and subclinical hypercortisolism [70], 68 patients with a tumour but no 
subclinical hypercortisolism, and 70 matched controls, both aBMD and TBS were lower in those 
with subclinical hypercortisolism. In addition, baseline lumbar TBS predicted incident fractures 
over a mean 40 months of follow-up, independent of patient age, BMI and lumbar aBMD [70].  
Type-2 Diabetes 
There is evidence that patients with type-2 diabetes fracture at higher aBMD than 
postmenopausal women [71].  As such, there is a need for improved approaches to estimate 
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fracture risk in such individuals. Recently, three studies have demonstrated that, although aBMD 
tends to be higher in type-2 diabetics than non-diabetics, the reverse is true of TBS. In the first 
paper, a cross-sectional case-control study by Dhaliwal et al., 57 women with type-2 diabetes 
were compared with 43 women without. TBS was lower and aBMD higher among diabetics (p = 
0.001 and 0.01, respectively).  Moreover, TBS was lower (p = 0.01) and aBMD no different in 
those diabetics with poor glycemic control compared to those with good glycemic control (an 
A1c above, versus below, 7.5%) [72]. The authors speculated that “abnormal architecture may 
help explain the paradox of increased fractures at higher aBMD” in these patients, although 
other mechanisms, such as glycosylation of collagen cross-links, key to the basic nano-structure 
of bone, have also been postulated [71].  Leslie et al [73] retrospectively analyzed data from 
29,407 Canadian women age 50 years or over, who had undergone a baseline DXA examination, 
comparing 2356 diagnosed diabetics with the remainder of the cohort.  After adjustment for 
clinical risk factors, diabetic women were found to be more likely to be in the lowest third of 
lumbar TBS, but less likely to be in the lowest thirds of lumbar, femoral neck or total hip aBMD. 
Both TBS and measures of aBMD were predictive of incident fracture. Finally, in the Ansung 
cohort, which included 1229 men and 1529 postmenopausal women (325 men and 370 women 
with type-2 diabetes) [74], lumbar spine TBS was lower in men and women with diabetes than 
those without, whereas lumbar spine BMD was higher in men and women with diabetes. 
Interestingly, TBS was negatively correlated with HbA1c, fasting plasma glucose and fasting 
insulin. Based on the above studies, TBS may aid fracture risk assessment in patients with type-
2 diabetes. 
Primary hyperparathyroidism 
Several studies provide support for use of lumbar TBS in the management of asymptomatic 
primary hyperparathyroidism [75-78].  Romagnoli et al [77] noted lower TBS in 73 post-
menopausal women with primary hyperparathyroidism (29 of them having a documented 
vertebral fracture) than in 74 age-matched controls.  In a study that included both cross-
sectional and longitudinal components, Eller-Vainicher et al [76] compared 92 patients with 
primary hyperparathyroidism (74 of them post-menopausal females and the remainder males 
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over age 50 years) and 98 controls with other conditions, consecutively recruited from clinic. 
Again, TBS was lower in patients with primary hyperparathyroidism than in controls, and was 
statistically significantly associated with vertebral fracture, even after adjustment for age, 
gender, BMI and lumbar spine aBMD (adjusted OR = 1.4; 95%CI: 1.1-1.9). In the longitudinal 
phase of the study, 20 primary hyperparathyroidism patients who underwent a 
parathroidectomy to achieve ‘cure’ were compared at 24 months follow-up with 10 patients 
treated conservatively. In the surgery group, the mean TBS z-score increased by 1.20 (p < 0.01), 
whilst TBS non-significantly declined in the ten conservatively-treated counterparts [76].  
Osteoarthritis 
One limitation of spinal aBMD assessment is that the presence of overlying calcifications due to 
degenerative change can erroneously elevate the resulting measurement. Recent studies have 
suggested that TBS may be less affected by such artefactual influences [79].  Both points were 
demonstrated in a recent study by Kolta et al. [80] in which 1254 post-menopausal women in 
the European OPUS cohort, mean age 67 years, underwent TBS measurement at baseline and 
again at a mean of six years later. The severity of spinal osteoarthritis was graded according to 
Kellgren and Lawrence [81]. The investigators found that TBS was no different in women with, 
versus without, osteoarthritic changes in the spine at baseline, while lumbar spine aBMD 
measurements averaged 5.7% higher in the former group (p< 0.003). Over a mean six years of 
follow-up, TBS declined by 3.3% (p < 0.001), independent of the severity of spinal osteoarthritis.  
Conversely, though femoral neck and total hip aBMD also decreased over time and were not 
affected by osteoarthritis grade, there was no net decrease in lumbar aBMD, which was also 
associated with the grade of spinal arthritis [82].  
Currently-published data support a role for the TBS in the assessment of fragility fracture risk in 
patients with a variety of secondary causes of osteoporosis, including subclinical 
hypercortisolism, type-2 diabetes, and parathyroid disease. Clearly, prospective cohort studies 
will be needed to confirm any added utility of TBS in these specific situations over and above its 
general predictive ability for fracture. 
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Conclusions 
In recent years, there has been increasing interest in the use of TBS, a surrogate of bone 
microarchitecture, for risk stratification in osteoporosis. The present assessment of the existing 
literature indicates that low lumbar spine TBS is associated with both a history of fracture and 
the incidence of new fracture. The effect is independent of aBMD and of sufficient magnitude to 
enhance risk stratification with aBMD.  The effect is also partly independent of FRAX with likely 
greatest utility for those individuals who lie close to an intervention threshold.  TBS increases 
with treatment for osteoporosis, but the magnitude of this change is smaller than that with 
bone mineral density; the relationship between change in TBS and magnitude of fracture risk 
reduction remains to be elucidated. There have been a number of smaller investigations, which 
have suggested that TBS may play a role in specific causes of increased fracture risk, such as 
glucocorticoid excess, hyperparathyroidism and type-2 diabetes.  
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Table 1.  Cross-sectional case control studies that examine TBS and fracture risk 
 
Year       TBS   BMD     
First Author Published Location Subjects Outcome(s) OR/SD decrease 95% CI OR/SD decrease 95% CI Adjustments 
                    
Pothuaud [34] 2009 Switzerland 135 PM females vertebral Fx 2.66 1.46, 4.85 NR NR none 
    France 45 cases with Fx hip Fx NR NR NR NR none 
      90 BMD-matched controls MOF 1.95 1.31, 2.89 NR NR none 
           se         
Winzenrieth [38] 2010 France 243 PM females vertebral Fx 1.97  1.31, 2.96 1.63 1.20, 2.22 weight 
      81 cases with vertebral Fx             
      162 age-matched controls             
                    
Rabier [35] 2010 France 168 PM females vertebral Fx 3.81  2.17, 6.72 2.48 1.61, 3.83 weight 
      42 cases vertebral Fx              
      126 age-matched controls             
                    
Lamy [30] 2012 Switzerland 631 PM women all Fx (self-report) 1.4 1.1, 1.7 1.3 1.1, 1.6 age, BMI 
      164 with Fx (53 VF, 107 MOF) vertebral Fx (VFA) 2.0 1.4, 3.0 1.8 1.2, 2.5 age, BMI 
      467 controls MOF 1.9 1.4, 2.5 1.6 1.2, 2.1 age, BMI 
                    
Del Rio [28] 2013 Spain 191 PM women femoral neck Fx  1.71 1.15, 2.79 1.94 1.35, 2.79 age 
      83 cases with Fx (self-report)           
      108 non-matched controls             
                    
Vasic [37] 2013 Serbia 1031 women MOF 1.27 1.07, 1.51 NR NR age, LS BMD 
  Bulgaria 271 with Fx       
  Ukrain        
  Romania        
Leib [32] 2014 USA 2165 women all Fx (self-report) 1.28 1.13,1.46 NR NR age, LS BMD, 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 28 
     289 cases with Fx       weight, smoking, 
     1876 non-matched controls           maternal history  
                 of hip fracture 
Krueger [29] 2014 USA 429 PM women fracture (self-report) 2.46 1.9, 3.1 1.36 1.2, 1.6 age, BMI 
      158 cases with Fx (91 vertebral Fx) vertebral Fx (VFA) 2.49 1.9, 3.3 1.36 1.1, 1.7   
      271 age-matched controls   
 
        
                    
Leib [31] 2014 USA 180 men  low-energy Fx 1.55 1.09, 2.20 NR NR age, LS BMD 
      45 cases with Fx (self-report)           
      135 age/LS-BMD matched  controls             
                    
Nassar [33] 2014 France 280 women, 82 men > age 50 vertebral Fx (VFA) vs. Non- vertebral Fx NR NR NR NR NR 
      133 vertebral Fx, 186 hip Fx AUC TBS > AUC BMD NR NR NR NR NR 
      176 non- vertebral Fx, non-hip Fx (0.67 vs. 0.54, p = 0.04)           
                    
Touvier [36] 2015 France 
255 women, 40-92 years 
79 fragility fracture 
176 controls 
Fragility fracture 
(orthopedic clinic) 2.25 1.58, 3.29 1.70 1.18, 2.54 Age 
PM = postmenopusal, Fx = fracture; MOF = major osteoporotic fracture; NR = not recorded 
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Table 2.  Prospective cohort studies that have examined lumbar TBS and fracture risk 
First Year       Follow-up 
Lumbar spine 
TBS 
  
Lumbar spine 
BMD 
  Total hip BMD     
author, ref 
number 
Published Location Subjects Outcome [years] HR or RR/SD* 95% CI HR or RR /SD* 95% CI HR or RR/SD* 95% CI Adjustments 
Hans [25] 2011 Canada 29,407 PM women clinical VF 4.7 1.45 1.32, 1.58 1.72 1.55, 1.91 1.75 1.58, 1.96 age 
      
5.7% OP Fx (1.5% 
clinical VFx; 
hip Fx   1.46 1.30, 1.63 1.31 1.16, 1.48 2.55 2.22, 2.93 age 
      1.0% hip Fx MOF   1.35 1.29, 1.42 1.47 1.39, 1.55 1.67 1.58, 1.76 age 
              
 
          
Boutroy [39] 2013 France OLEFY cohort clinical VF 8 1.34 1.04, 1.73 1.3 1.06, 1.58 1.99 1.52, 2.62 age, weight 
      560 PM women radiographic VF                 
      94 with Fx at any site fragility Fx                 
                          
Briot [40] 2013 France OPUS cohort radiographic VF  6 1.54 1.17, 2.03 1.75 1.25, 2.48 1.73 1.26, 2.38 none 
    UK 1007 PM women clinical OP Fx   1.62 1.30, 2.01 1.47 1.16, 1.89 1.65 1.30, 2.11   
    Germany 
8.1% with OP Fx; 
4.6% with VF 
    
 OR per SD 
decrease 
  
 OR per SD 
decrease 
  
OR  per SD 
decrease 
    
                          
Iki [41] 2014 Japan 665 PM women VF (VFA) 8.3 1.54 1.17, 2.02 1.27 1.02, 1.59 NR NR age, LS BMD 
      92 with VF     
 OR per SD 
decrease  
  
 OR per SD 
decrease  
        
                          
Leslie [54] 2014a Canada 
3620 men > 50 
(mean age 67.6) 
MOF 4.5 1.22 1.60, 1.41 1.14 1.02, 1.28 1.66 1.40, 1.98 FRAX score, 
      
183 MOF (91 VF, 46 
hip Fx) 
hip Fx   1.6 1.21, 2.11 1.29 1.03, 1.60 2.84 1.95, 4.12 treatment 
        VF   1.12 0.91, 1.38 1.26 1.09, 1.47 1.2 0.95, 1.51   
                          
Leslie [43] 2014b Canada 
33,352 women 40-
100 years 
MOF 
  
1.36 1.30,1.42 NR 
  
NR 
  
Time since 
baseline and 
age 
        Death   1.32 1.26,1.39           
        
          
McCloskey 
[42] 
2015 Multinational 
17809  
men & women 
MOF 6.7 1.32 1.24, 1.41 NR   NR   
FRAX score, 
time since 
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baseline and 
age 
      298 with hip hip Fx   1.28 1.13, 1.45           
      1109 with MOF Men MOF   1.35 1.21, 1.49           
        Men hip Fx   1.27 1.06, 1.53           
        Women MOF   1.31 1.21, 1.42           
        Women hip Fx   1.29 1.09, 1.52           
*Hazard ratio or relative risk per SD decrease in predictor unless otherwise stated 
PM = postmenopusal, Fx = fracture; MOF = major osteoporotic fracture; VFx = vertebral fracture; NR = not recorded 
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Table 3: Treatment related changes in lumbar TBS  
First Year   Study   TBS Versus Versus BMD Versus Versus 
author Published Location design Subjects change/yr baseline other Rx change/yr baseline other Rx 
                      
Krieg [50] 2013 Canada Case-control 534 PM women on standard OP Rx 0.20% p < 0.001 p < 0.001 1.90% p < 0.002 p < 0.001 
        1150 untreated -0.30% p < 0.001   -0.40% p < 0.001   
                      
Popp [53] 2013 Switzerland RCT 54 PM women on zoledronate 0.50% p < 0.001 p < 0.001 3.20% p < 0.001 p < 0.001 
        53 on placebo -0.20% p < 0.001   0.50% p < 0.001   
                      
Senn [59] 2014 Switzerland Open-Label 65 PM women on teriparatide 2.20% p < 0.001 p < 0.001 3.80% p < 0.001 p < 0.001 
        122 PM women on ibandronate 0.20% p = 0.86   1.50% p < 0.001   
                      
Kalder [49] 2014 Germany RCT substudy 17 PM women on tamoxifen 1.70% p < 0.06 p < 0.001 1.00% NS p < 0.001 
        19 PM women on exemestane -1.20% p < 0.05   -2.70% p < 0.002   
                      
Petranova 
[58] 
2014 Bulgaria Observational 36 PM women on denosumab 1.70% p < 0.05 NA       
        no controls             
                      
Kalder [57] 2015 Germany RCT 34 women with breast cancer on zoledronate 2.41% p<0.006 p=0.003 2.17% p<0.001 p<0.005 
        36 women with breast cancer on placebo -0.52%     -5.02%     
                      
Di Gregorio 
[56] 
2015 Spain Open-Label 67 untreated -1.55% p<0.05   0.25% NS   
        87 men and women on calcium and vitamin D 0.65% NS NA 0.80% NS NA 
        88 men and women on Alendronate 0.70% p<0.05 NA 2.05% p<0.001 NA 
        36 men on Testosterone 0.90% NS NA 2.20% p<0.001 NA 
        39 men and women on Risedronate 0.70% NS NA 2.40% p<0.001 NA 
        43 men and women on Denosumab 1.40% p<0.01 NA 4.40% p<0.001 NA 
        30 men and women on Teriparatide 1.80% p<0.01 NA 4.40% p<0.001 NA 
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PM = postmenopusal; NA = not applicable 
